FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...

Even beyond the pendulum lurches between presidencies, many of the perennial debates over education policy, politics, and ...

DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth ...

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused ...

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

MRI is the ideal imaging modality for initial evaluation and diagnosis of testicular cancer.

Updates include sex-neutral requirements for all combat MOS Marines to score a minimum of 210 out of a possible 300.

Study’s findings suggest there has been progress in treating the disorder, the researchers say, they also raise concerns ...

Combat roles in the Marines have had gender-neutral requirements since 2015. A new policy extends that rule to fitness test scores.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...